CA2301871A1 - Alteration fonctionnelle du gene brca2 dans des cellules et des animaux transgeniques non humains - Google Patents
Alteration fonctionnelle du gene brca2 dans des cellules et des animaux transgeniques non humains Download PDFInfo
- Publication number
- CA2301871A1 CA2301871A1 CA002301871A CA2301871A CA2301871A1 CA 2301871 A1 CA2301871 A1 CA 2301871A1 CA 002301871 A CA002301871 A CA 002301871A CA 2301871 A CA2301871 A CA 2301871A CA 2301871 A1 CA2301871 A1 CA 2301871A1
- Authority
- CA
- Canada
- Prior art keywords
- brca2
- cells
- gene
- impaired
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241001465754 Metazoa Species 0.000 title claims description 27
- 230000009261 transgenic effect Effects 0.000 title claims description 17
- 230000001771 impaired effect Effects 0.000 title abstract description 24
- 210000004027 cell Anatomy 0.000 claims abstract description 143
- 101150008921 Brca2 gene Proteins 0.000 claims abstract description 100
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 69
- 230000035772 mutation Effects 0.000 claims abstract description 48
- 230000002950 deficient Effects 0.000 claims abstract description 9
- 230000002028 premature Effects 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 39
- 108700028369 Alleles Proteins 0.000 claims description 36
- 238000012217 deletion Methods 0.000 claims description 24
- 230000037430 deletion Effects 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 108700019146 Transgenes Proteins 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 9
- 238000004458 analytical method Methods 0.000 claims description 7
- 230000002018 overexpression Effects 0.000 claims description 7
- 210000004102 animal cell Anatomy 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 5
- 230000002068 genetic effect Effects 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 210000001161 mammalian embryo Anatomy 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 230000003362 replicative effect Effects 0.000 claims description 2
- 230000005014 ectopic expression Effects 0.000 claims 5
- 230000009452 underexpressoin Effects 0.000 claims 4
- 230000022131 cell cycle Effects 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 230000037442 genomic alteration Effects 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 38
- 241000699670 Mus sp. Species 0.000 abstract description 26
- 230000006870 function Effects 0.000 abstract description 23
- 101100437875 Mus musculus Brca2 gene Proteins 0.000 abstract description 18
- 102000004169 proteins and genes Human genes 0.000 abstract description 17
- 210000002257 embryonic structure Anatomy 0.000 abstract description 15
- 230000008439 repair process Effects 0.000 abstract description 13
- 102000052609 BRCA2 Human genes 0.000 abstract description 7
- 108700020462 BRCA2 Proteins 0.000 abstract description 7
- 230000008943 replicative senescence Effects 0.000 abstract description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 6
- 230000037361 pathway Effects 0.000 abstract description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 abstract description 5
- 231100000024 genotoxic Toxicity 0.000 abstract description 5
- 230000001738 genotoxic effect Effects 0.000 abstract description 5
- 230000005865 ionizing radiation Effects 0.000 abstract description 5
- 230000013120 recombinational repair Effects 0.000 abstract description 4
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 3
- 206010006187 Breast cancer Diseases 0.000 abstract description 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 2
- 208000005623 Carcinogenesis Diseases 0.000 abstract description 2
- 101100355599 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mus-11 gene Proteins 0.000 abstract description 2
- 101150006234 RAD52 gene Proteins 0.000 abstract description 2
- 102000053062 Rad52 DNA Repair and Recombination Human genes 0.000 abstract description 2
- 108700031762 Rad52 DNA Repair and Recombination Proteins 0.000 abstract description 2
- 230000036952 cancer formation Effects 0.000 abstract description 2
- 231100000504 carcinogenesis Toxicity 0.000 abstract description 2
- 231100000722 genetic damage Toxicity 0.000 abstract description 2
- 210000004962 mammalian cell Anatomy 0.000 abstract description 2
- 230000010534 mechanism of action Effects 0.000 abstract description 2
- 230000036961 partial effect Effects 0.000 abstract description 2
- 238000001086 yeast two-hybrid system Methods 0.000 abstract description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 abstract 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 abstract 1
- 239000013598 vector Substances 0.000 description 60
- 230000008685 targeting Effects 0.000 description 38
- 108020004414 DNA Proteins 0.000 description 32
- 239000003550 marker Substances 0.000 description 25
- 239000012634 fragment Substances 0.000 description 23
- 108091034117 Oligonucleotide Proteins 0.000 description 19
- 239000002773 nucleotide Substances 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 12
- 210000001671 embryonic stem cell Anatomy 0.000 description 11
- 230000000692 anti-sense effect Effects 0.000 description 10
- 238000010367 cloning Methods 0.000 description 10
- 210000002950 fibroblast Anatomy 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 238000010363 gene targeting Methods 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 101150003028 Hprt1 gene Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002744 homologous recombination Methods 0.000 description 7
- 230000006801 homologous recombination Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 5
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 210000002459 blastocyst Anatomy 0.000 description 5
- 230000002759 chromosomal effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 101150003725 TK gene Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000005782 double-strand break Effects 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 208000001608 teratocarcinoma Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000006822 Agouti Signaling Protein Human genes 0.000 description 3
- 108010072151 Agouti Signaling Protein Proteins 0.000 description 3
- 241000484025 Cuniculus Species 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- 101100300807 Drosophila melanogaster spn-A gene Proteins 0.000 description 3
- 241000701959 Escherichia virus Lambda Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000033607 mismatch repair Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000009758 senescence Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- IPVFGAYTKQKGBM-BYPJNBLXSA-N 1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 IPVFGAYTKQKGBM-BYPJNBLXSA-N 0.000 description 2
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241001646716 Escherichia coli K-12 Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000002987 choroid plexus Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000013601 cosmid vector Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 231100000299 mutagenicity Toxicity 0.000 description 2
- 230000007886 mutagenicity Effects 0.000 description 2
- 230000020520 nucleotide-excision repair Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 101100328086 Caenorhabditis elegans cla-1 gene Proteins 0.000 description 1
- 101100257127 Caenorhabditis elegans sma-2 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000251204 Chimaeridae Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000699662 Cricetomys gambianus Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 241001452028 Escherichia coli DH1 Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 240000005702 Galium aparine Species 0.000 description 1
- 235000014820 Galium aparine Nutrition 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 102000015335 Ku Autoantigen Human genes 0.000 description 1
- 108010025026 Ku Autoantigen Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 101100355584 Mus musculus Rad51 gene Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101800000684 Ribonuclease H Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 101150118680 aflR gene Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000008049 biological aging Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 231100000244 chromosomal damage Toxicity 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 101150108701 toa2 gene Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005820 transferase reaction Methods 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Animal Husbandry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
ScRad51, élément du groupe épistatique RAD52 de Saccharomyces cerevisiae, est un composant important de la voie de réparation par recombinaison utilisé pour réparer les dégâts génétiques provoqués par les rayonnements ionisants. L'homologue murin de ScRad51, MmRad51, semble posséder une fonction similaire; cependant le mécanisme précis d'action n'est pas bien compris. Les associations protéine:protéine sont critiques pour la fonction de ScRad51. Par conséquent, on a utilisé le système de levure à deux hybrides pour isoler des protéines qui s'associent à MmRad51, dans le but de mieux comprendre la réparation par recombinaison dans les cellules mammaliennes et l'on a isolé le Brca2 murin. Chez les humains, BRCA2 est un gène suppresseur de tumeur, important dans l'étiologie du cancer du sein. Une comparaison phénotypique entre MmRad51 et des embryons et des cellules présentant une carence en Brca2 suggère que l'association protéine:protéine est importante pour leur fonction. De même que pour MmRad51, la fonction du Brca2 est critique s'agissant de la réparation des dégâts occasionnés par les rayonnements gamma. En outre, une mutation subtile qui retire seulement la petite fraction de Brca2 qui s'associe à MmRad51, soit directement soit indirectement, présente un phénotype qui suggère une fonction partielle. Ces cellules mutantes homozygotes sont viables, quoiqu'hypersensibles aux rayonnements ionisants et subissent une sénescence réplicative prématurée. On a ainsi créé des cellules et des souris présentant une altération fonctionnelle du gène Brca2, qui devraient s'avérer utiles en tant que modèle tumorigène destiné à l'analyse d'agents génotoxiques et en tant qu'outil d'étude de la sénescence réplicative prématurée.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5697397P | 1997-08-26 | 1997-08-26 | |
| US60/056,973 | 1997-08-26 | ||
| PCT/US1998/017566 WO1999010479A1 (fr) | 1997-08-26 | 1998-08-25 | Alteration fonctionnelle du gene brca2 dans des cellules et des animaux transgeniques non humains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2301871A1 true CA2301871A1 (fr) | 1999-03-04 |
Family
ID=22007720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002301871A Abandoned CA2301871A1 (fr) | 1997-08-26 | 1998-08-25 | Alteration fonctionnelle du gene brca2 dans des cellules et des animaux transgeniques non humains |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1025203A4 (fr) |
| JP (1) | JP2001513991A (fr) |
| AU (1) | AU757433B2 (fr) |
| CA (1) | CA2301871A1 (fr) |
| WO (1) | WO1999010479A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU778719B2 (en) | 1999-07-14 | 2004-12-16 | Transgenic Inc. | Trap vector and gene trapping method by using the same |
| US6531644B1 (en) * | 2000-01-14 | 2003-03-11 | Exelixis, Inc. | Methods for identifying anti-cancer drug targets |
| JP2001211882A (ja) * | 2000-01-31 | 2001-08-07 | Shiyuuji Miyagawa | 移植関連タンパク質をコードするコドン改変型遺伝子 |
| CA2432976A1 (fr) * | 2000-12-21 | 2002-08-08 | Board Of Trustees Of The University Of Illinois | Reactifs et procedes d'identification et de modulation de l'expression de genes de senescence tumorale |
| AU2002359398A1 (en) * | 2001-11-16 | 2003-06-10 | Exelixis, Inc. | Nucleic acids and polypeptides of invertebrate brca2 and methods of use |
-
1998
- 1998-08-25 WO PCT/US1998/017566 patent/WO1999010479A1/fr active IP Right Grant
- 1998-08-25 CA CA002301871A patent/CA2301871A1/fr not_active Abandoned
- 1998-08-25 AU AU90334/98A patent/AU757433B2/en not_active Ceased
- 1998-08-25 JP JP2000507787A patent/JP2001513991A/ja active Pending
- 1998-08-25 EP EP98942233A patent/EP1025203A4/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1025203A1 (fr) | 2000-08-09 |
| JP2001513991A (ja) | 2001-09-11 |
| EP1025203A4 (fr) | 2003-06-04 |
| WO1999010479A1 (fr) | 1999-03-04 |
| AU9033498A (en) | 1999-03-16 |
| AU757433B2 (en) | 2003-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Thompson et al. | Germ line transmission and expression of a corrected HPRT gene produced by gene targeting in embryonic stem cells | |
| TsUZUKI et al. | Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. | |
| US5589369A (en) | Cells homozygous for disrupted target loci | |
| US6461864B1 (en) | Methods and vector constructs for making non-human animals which ubiquitously express a heterologous gene | |
| US20060075511A1 (en) | Muir-Torre-like syndrome in Fhit deficient mice | |
| US5907079A (en) | MSH2 disrupted mice develop lymphomas | |
| JP2007259871A (ja) | 細胞周期を仲介する組成物および方法 | |
| EP1325144A2 (fr) | Nouveaux vecteurs chromosomiques et utilisations de ceux-ci | |
| US20050177887A1 (en) | Somatic cells, germ cells and cell lines derived from a PTTG knockout rodent | |
| AU757433B2 (en) | Impaired BRCA2 function in cells and non-human transgenic animals | |
| JP2001211782A (ja) | ｔｏｂ遺伝子欠損ノックアウト非ヒト哺乳動物 | |
| US5955644A (en) | Ku deficient cells and non-human transgenic animals | |
| US6642433B1 (en) | Fgl-2 knockout mice | |
| WO1993019166A1 (fr) | Petits animaux modeles pour l'etude de metabolisme du cholesterol | |
| US5994620A (en) | Induced chromosomal deletion | |
| US6057489A (en) | MmRad51-deficient cells and transgenic mice | |
| US5948952A (en) | Xeroderma pigmentosum-deficient mouse | |
| WO1999037756A1 (fr) | Animal non humain possedant un gene slp-76 a disruption fonctionnelle | |
| WO1998046733A1 (fr) | Transfert chromosomique (xmmct) dans des cellules es induit lors de l'exposition de microcellules a un rayonnement | |
| US7151200B2 (en) | Histamine receptor H3 modified transgenic mice | |
| JP4030342B2 (ja) | 遺伝子欠損細胞 | |
| CN115819553A (zh) | 一种il1rl2和/或il36a基因人源化的非人动物及其构建方法和应用 | |
| WO2006022361A1 (fr) | ANIMAL DÉFICIENT EN GÈNE Psf1 ET PROCÉDÉ D'UTILISATION DE CELUI-CI | |
| US20080196114A1 (en) | Rgmc Modified Transgenic Animals | |
| JP2004105049A (ja) | 非ヒトモデル動物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20070827 |